Search

Your search keyword '"Maughan, Timothy"' showing total 410 results

Search Constraints

Start Over You searched for: Author "Maughan, Timothy" Remove constraint Author: "Maughan, Timothy"
410 results on '"Maughan, Timothy"'

Search Results

1. Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer

2. Identification and validation of a machine learning model of complete response to radiation in rectal cancer reveals immune infiltrate and TGFβ as key predictors

3. Author Correction: Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer

4. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis

6. Author Correction: Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features

7. Joint Prediction of Response to Therapy, Molecular Traits, and Spatial Organisation in Colorectal Cancer Biopsies

8. Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries

9. Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Responsep53 Pathway SNPs and Mutations Interact to Affect Cancer

11. Enhancing Local Context of Histology Features in Vision Transformers

13. Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units

15. Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features

16. Author Correction: Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries

17. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project

20. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial

22. Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis

23. Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33

27. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

28. supplementary figures, from In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer

29. Data from Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response

30. Supplementary Results from In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer

31. Supplementary Tables S1-5 and Figure S1 from Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival

33. Supplementary Figure 2 from Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab

34. Supplementary Data from Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response

35. Supplementary Figure 3 from Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab

36. Supplementary Figure Legends from Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab

37. Supplementary Figure 1 from Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab

38. Supplementary Materials and Methods and Tables 1-5 from Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab

39. Supplementary Data from In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer

41. Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer

42. The polymorphic variant rs1800734 influences methylation acquisition and allele-specific TFAP4 binding in the MLH1 promoter leading to differential mRNA expression

44. Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2)

46. Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries

47. Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT

48. Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia

49. Erratum: Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia (Cell Stem Cell (2022) 29(8) (1213–1228.e8), (S1934590922003034), (10.1016/j.stem.2022.07.008))

Catalog

Books, media, physical & digital resources